Dengue-Associated HLH Treatment
For dengue-associated HLH, initiate a short course (3-4 days) of high-dose corticosteroids (dexamethasone 10 mg/m² daily) as first-line therapy, which can achieve favorable outcomes without requiring etoposide in most cases. 1
Treatment Algorithm
Initial Management Approach
Dengue-associated HLH differs fundamentally from other infection-triggered HLH because immunosuppression should be avoided when patients respond well to specific antimicrobial treatment 2. The key distinction is that dengue is a self-limited viral infection where the primary pathogen targets the monocyte-macrophage system.
Start with corticosteroids alone:
- Dexamethasone 10 mg/m² daily for 3-4 days 1
- Alternative: Prednisolone 1-2 mg/kg daily 2
- Consider adding IVIG 1.6 g/kg divided over 2-3 days 2
When to Escalate Therapy
Reserve etoposide for severe presentations only:
- Imminent organ failure
- Rapid clinical deterioration despite corticosteroids
- Refractory disease after initial steroid course
The 2019 Blood guidelines emphasize that for infection-associated HLH where pathogens target the monocyte-macrophage system, the full HLH-94 protocol with etoposide should be avoided because these patients typically respond to pathogen-specific treatment plus anti-inflammatory therapy 2.
Graded Intensity Based on Severity
Mild-to-moderate disease (stable patient):
- Short course corticosteroids ± IVIG
- Close monitoring of ferritin, sCD25, cell counts
- Supportive care
Severe disease (deteriorating patient):
- High-dose dexamethasone 10 mg/m²
- Consider etoposide (modified dose if renal impairment present) 2
- IVIG 1.6 g/kg over 2-3 days
- Intensive supportive care
Novel Therapies (Emerging Evidence)
Recent case reports demonstrate successful outcomes with:
- Tocilizumab (IL-6 receptor blocker) - first reported successful use in dengue-associated HLH 3
- Anakinra (IL-1R antagonist) - used successfully in dengue-induced HLH with multi-organ failure 4
These biologics may be considered for refractory cases or severe presentations, though evidence remains limited to case reports.
Critical Diagnostic Considerations
Suspect dengue-associated HLH when:
- Prolonged or recurrent fever >7 days
- Anemia without intravascular hemolysis or massive bleeding
- Progressive cytopenias despite supportive dengue management
- Persistent fever with deteriorating hematological parameters 1, 5
Confirm diagnosis: Fulfill ≥5 of 8 HLH-2004 criteria, including bone marrow examination showing hemophagocytosis 1, 5
Important Caveats
Avoid Overtreatment
A critical pitfall is initiating aggressive HLH-directed therapy in patients with self-limited dengue-associated immune activation. Recent evidence shows that dynamic longitudinal assessment of recovery patterns (spontaneous defervescence, reticulocyte recovery, platelet rebound, declining ferritin) may identify patients who can be safely observed without immunosuppression 6.
Monitoring Parameters
- Ferritin levels (trend more important than absolute value)
- sCD25 (soluble IL-2 receptor)
- Complete blood counts with reticulocyte count
- Fibrinogen and triglycerides
- Liver function tests
Bone Marrow Recovery
Etoposide should be used sparingly in dengue-associated HLH because bone marrow recovery is central for immune reconstitution 2. The myelosuppressive effects of etoposide may compound dengue-related cytopenias and delay recovery.
Infection Prophylaxis
If HLH-directed immunosuppressive therapy is required:
- Broad antimicrobial prophylaxis against Pneumocystis jirovecii and fungi
- Consider antiviral prophylaxis due to T-cell depletion 2
Prognosis
Mortality in adult HLH ranges from 20-88% 2, but dengue-associated HLH can have favorable outcomes with steroid therapy alone 1. Early recognition and prompt treatment initiation are critical to preventing progression to refractory disease and multi-organ failure.
Contact an HLH reference center for refractory cases requiring individualized salvage approaches 2.